NCT05540262 Edaravone in the Treatment of Optic Neuritis
| NCT ID | NCT05540262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Guangxi Medical University |
| Condition | Optic Neuritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-01-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2022-01-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Eligibility Criteria
Inclusion Criteria: 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: 1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Frequently Asked Questions
Who can join the NCT05540262 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Optic Neuritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05540262 currently recruiting?
Yes, NCT05540262 is actively recruiting participants. Visit ClinicalTrials.gov or contact First Affiliated Hospital of Guangxi Medical University to inquire about joining.
Where is the NCT05540262 trial being conducted?
This trial is being conducted at Nanning, China.
Who is sponsoring the NCT05540262 clinical trial?
NCT05540262 is sponsored by First Affiliated Hospital of Guangxi Medical University. The trial plans to enroll 50 participants.